2025
Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling
Guillemaud M, Chavez M, Kobeissy F, Vezzani A, Jimenez A, Basha M, Batra A, Demeret S, Eka O, Eschbach K, Foreman B, Gaspard N, Gerard E, Gofton T, Haider H, Hantus S, Howe C, Jongeling A, Kalkach-Aparicio M, Kandula P, Kazazian K, Kim M, Lai Y, Marois C, Mellor A, Mohamed W, Morales M, Pimentel C, Ramirez A, Steriade C, Struck A, Taraschenko O, Torcida Sedano N, Wainwright M, Yoo J, Wang K, Navarro V, Hirsch L, Hanin A. Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling. Neurology Neuroimmunology & Neuroinflammation 2025, 12: e200403. PMID: 40334176, PMCID: PMC12063244, DOI: 10.1212/nxi.0000000000200403.Peer-Reviewed Original ResearchConceptsCryptogenic new-onset refractory status epilepticusClusters of patientsCytokine profileInflammatory markersNew-onset refractory status epilepticusTarget specific inflammatory pathwaysInitiation of immunotherapyResponse to immunotherapyRefractory status epilepticusPersonalized therapeutic strategiesGroup of patientsStatistically significant elevationTime of administrationProtein pathway analysisInflammatory subgroupsMultiple immunotherapiesDifferential treatment responseRefractory SEC patientsImprove patient outcomesAutoimmune mechanismsImmune dysregulationClinical featuresCytokine levelsAutoimmune process
2023
Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatric Endocrinology Diabetes And Metabolism 2023, 29: 1-3. PMID: 37218722, PMCID: PMC10226454, DOI: 10.5114/pedm.2023.126360.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBeta-cell functionType 1 diabetesIslet autoimmunityCell functionFunctional beta-cell massDisease-modifier drugsUnderlying autoimmune processPre-symptomatic phaseBeta-cell massSymptomatic diabetesAutoimmune processClinical onsetSurrogate markerDiabetes progressionC-peptideInsulin secretionModifier drugsEarly changesDiabetesMetabolic changesDysglycaemiaAutoimmunityT1DOnsetModifier treatment
2022
Blood-Based Biomarkers of Repetitive, Subconcussive Blast Overpressure Exposure in the Training Environment: A Pilot Study
Agoston D, McCullough J, Aniceto R, Lin I, Kamnaksh A, Eklund M, Graves W, Dunbar C, Engall J, Schneider E, Leonessa F, Duckworth J. Blood-Based Biomarkers of Repetitive, Subconcussive Blast Overpressure Exposure in the Training Environment: A Pilot Study. Neurotrauma Reports 2022, 3: 479-490. PMID: 36337080, PMCID: PMC9634979, DOI: 10.1089/neur.2022.0029.Peer-Reviewed Original ResearchTraumatic brain injuryMatrix metalloprotease-9Serum levelsClaudin-5Ubiquitin C-terminal hydrolase L1Pilot studyUnknown long-term effectsElevated autoantibody titersGlial fibrillary acidic proteinMild traumatic brain injuryElevated serum levelsBlood-based biomarkersAlpha 7 subunitChronic degenerative processMolecular changesFibrillary acidic proteinBlast overpressure exposureAutoantibody titersAutoimmune processVascular changesElevated titersBrain injuryLong-term effectsBlood samplesMetalloprotease-9
2021
Inflammasomes and Type 1 Diabetes
Pearson JA, Wong FS, Wen L. Inflammasomes and Type 1 Diabetes. Frontiers In Immunology 2021, 12: 686956. PMID: 34177937, PMCID: PMC8219953, DOI: 10.3389/fimmu.2021.686956.Peer-Reviewed Original ResearchConceptsType 1 diabetesMultiprotein complexesEnhanced toleranceMicrobial ligandsIslet autoantibody developmentImmune responseGenetic associationMicrobial stimulationAvailable inhibitorsImportant modulatorType 1 diabetes susceptibilityPathwayDiabetes susceptibilityAutoimmune processMicrobiota compositionAutoantibody developmentMicrobiotaAnimal modelsInflammasomeActivationGenetic riskType 1DiabetesHumansRoleThe immune system and autism spectrum disorder: association and therapeutic challenges
Heidari A, Rostam–Abadi Y, Rezaei N. The immune system and autism spectrum disorder: association and therapeutic challenges. Acta Neurobiologiae Experimentalis 2021, 81: 249-263. PMID: 34672295, DOI: 10.21307/ane-2021-023.Peer-Reviewed Original ResearchConceptsCentral nervous systemPlasma levels of pro-inflammatory cytokinesPrevalence of autoimmune disordersImmune systemLevels of pro-inflammatory cytokinesFirst-degree family membersAutism spectrum disorderPro-inflammatory cytokinesAnti-inflammatory drugsInnate immune systemDevelopment of autism spectrum disorderAutoimmune involvementDefinitive treatmentAutoimmune processAutoimmune disordersImmunological factorsPlasma levelsGut-brain axisTriggering inflammationASD patientsHighest prevalenceNervous systemPathogenesisASD pathogenesisGenetic factors
2019
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
Patsopoulos N, Baranzini S, Santaniello A, Shoostari P, Cotsapas C, Wong G, Beecham A, James T, Replogle J, Vlachos I, McCabe C, Pers T, Brandes A, White C, Keenan B, Cimpean M, Winn P, Panteliadis I, Robbins A, Andlauer T, Zarzycki O, Dubois B, Goris A, Søndergaard H, Sellebjerg F, Sorensen P, Ullum H, Thørner L, Saarela J, Cournu-Rebeix I, Damotte V, Fontaine B, Guillot-Noel L, Lathrop M, Vukusic S, Berthele A, Pongratz V, Buck D, Gasperi C, Graetz C, Grummel V, Hemmer B, Hoshi M, Knier B, Korn T, Lill C, Luessi F, Mühlau M, Zipp F, Dardiotis E, Agliardi C, Amoroso A, Barizzone N, Benedetti M, Bernardinelli L, Cavalla P, Clarelli F, Comi G, Cusi D, Esposito F, Ferrè L, Galimberti D, Guaschino C, Leone M, Martinelli V, Moiola L, Salvetti M, Sorosina M, Vecchio D, Zauli A, Santoro S, Mancini N, Zuccalà M, Mescheriakova J, van Duijn C, Bos S, Celius E, Spurkland A, Comabella M, Montalban X, Alfredsson L, Bomfim I, Gomez-Cabrero D, Hillert J, Jagodic M, Lindén M, Piehl F, Jelčić I, Martin R, Sospedra M, Baker A, Ban M, Hawkins C, Hysi P, Kalra S, Karpe F, Khadake J, Lachance G, Molyneux P, Neville M, Thorpe J, Bradshaw E, Caillier S, Calabresi P, Cree B, Cross A, Davis M, de Bakker P, Delgado S, Dembele M, Edwards K, Fitzgerald K, Frohlich I, Gourraud P, Haines J, Hakonarson H, Kimbrough D, Isobe N, Konidari I, Lathi E, Lee M, Li T, An D, Zimmer A, Madireddy L, Manrique C, Mitrovic M, Olah M, Patrick E, Pericak-Vance M, Piccio L, Schaefer C, Weiner H, Lage K, Compston A, Hafler D, Harbo H, Hauser S, Stewart G, D’Alfonso S, Hadjigeorgiou G, Taylor B, Barcellos L, Booth D, Hintzen R, Kockum I, Martinelli-Boneschi F, McCauley J, Oksenberg J, Oturai A, Sawcer S, Ivinson A, Olsson T, De Jager P. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019, 365 PMID: 31604244, PMCID: PMC7241648, DOI: 10.1126/science.aav7188.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCell Cycle ProteinsChromosome MappingChromosomes, Human, XGene FrequencyGenetic LociGenome-Wide Association StudyGenomicsGTPase-Activating ProteinsHumansInheritance PatternsMajor Histocompatibility ComplexMicrogliaMultiple SclerosisPolymorphism, Single NucleotideQuantitative Trait LociRNA-SeqTranscriptomeConceptsMajor histocompatibility complexMultiple sclerosisImmune cellsBrain-resident immune cellsPeripheral immune cellsPeripheral immune responseCentral nervous systemExtended major histocompatibility complexAutoimmune processControl subjectsHuman microgliaImmune responseNervous systemImmune systemHistocompatibility complexPutative susceptibility genesMicrogliaX variantGenetic architectureSusceptibility genesGenomic mapGenetic dataExpression profilesM geneSusceptibility variants
2015
Epidemiology of multiple sclerosis: results from a large observational study in the UK
Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander M. Epidemiology of multiple sclerosis: results from a large observational study in the UK. Journal Of Neurology 2015, 262: 2033-2041. PMID: 26067217, PMCID: PMC4768220, DOI: 10.1007/s00415-015-7796-2.Peer-Reviewed Original ResearchConceptsUnderlying autoimmune processHazard ratioCause mortalityAutoimmune processMS patientsUK Clinical Practice Research DatalinkClinical Practice Research DatalinkIncident MS casesAdjusted hazard ratioUrinary tract infectionCox proportional regressionMultiple sclerosis progressionPrimary care dataConfidence intervalsLarge observational studiesIdentification of predictorsOriginal medical recordsCurrent smokingPatient comorbiditiesTract infectionsFrequent comorbiditiesLifestyle factorsMS diagnosisMultiple sclerosisPatient groupThe development of next-generation screening and diagnostic platforms will change diabetes care
Kumar R, Gupta M, Feldman B. The development of next-generation screening and diagnostic platforms will change diabetes care. Expert Review Of Molecular Diagnostics 2015, 15: 291-294. PMID: 25583407, PMCID: PMC4627787, DOI: 10.1586/14737159.2015.1002468.Peer-Reviewed Original Research
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisC-peptide levelsCharacteristics of patientsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
2009
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr J, Cengiz E, Tamborlane WV. From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today 2009, 14: 973-981. PMID: 19580883, DOI: 10.1016/j.drudis.2009.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoimmunityBiosensing TechniquesBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Drug Therapy, CombinationGlycated HemoglobinHumansHypoglycemic AgentsImmunologic FactorsInfusion PumpsInsulinInsulin-Secreting CellsPancreas, ArtificialPrimary PreventionTreatment OutcomeConceptsContinuous subcutaneous insulin infusionContinuous glucose monitoringType 1 diabetes mellitusBeta-cell destructionRapid-acting insulinSubcutaneous insulin infusionTreatment of T1DMType 1 diabetesBlood glucose fluctuationsImproved insulin deliveryAutoimmune processDiabetes mellitusPediatric patientsSecondary interventionsTreatment optionsInsulin infusionNew medicationsGlucose fluctuationsGlucose monitoringInsulin deliveryArtificial pancreasPreventionTreatmentInitial studyMellitus
2008
Multiple Sclerosis and Regulatory T Cells
Hutton J, Baecher-Allan C, Hafler D. Multiple Sclerosis and Regulatory T Cells. 2008, 265-277. DOI: 10.1007/978-0-387-77909-6_13.Peer-Reviewed Original ResearchRegulatory T cellsAutoreactive T cellsMultiple sclerosisT cellsAntigen-specific Treg cellsImmunopathology of MSCentral nervous system white matterAutoimmune tissue damageFrequency of TregsNervous system white matterOrgan-specific autoimmunityEffector T cellsReactive T cellsImmunosuppressive therapyTreg cellsAutoimmune processMS patientsPeripheral toleranceSpecific autoimmunityImmune disordersNew therapiesHealthy individualsB cellsWhite matterTissue damage
2005
Multiple sclerosis
Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher‐Allan C. Multiple sclerosis. Immunological Reviews 2005, 204: 208-231. PMID: 15790361, DOI: 10.1111/j.0105-2896.2005.00240.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMultiple sclerosisT cellsB cellsImmunopathology of MSCentral nervous system white matterNervous system white matterRegulatory T cellsHallmark of inflammationImmunosuppressive therapyAutoimmune processImmunomodulatory therapeuticsAnimal modelsMS researchWhite matterDisease pathologyClonal expansionDiseaseMajor histocompatibility complex (MHC) genesMolecular pathologyRNA expressionSclerosisInflammationTherapyPathologyComplex genetic diseases
2004
Lymphoplasmacytic sclerosing pancreato-cholangitis: a case report and review of the literature.
Prasad P, Salem RR, Mangla R, Aslanian H, Jain D, Lee J. Lymphoplasmacytic sclerosing pancreato-cholangitis: a case report and review of the literature. The Yale Journal Of Biology And Medicine 2004, 77: 143-8. PMID: 15989743, PMCID: PMC2259126.Peer-Reviewed Original ResearchConceptsChronic pancreatitisAutoimmune pancreatitisPancreatic ductNon-alcoholic duct-destructive chronic pancreatitisDuct-destructive chronic pancreatitisPylorus-preserving Whipple procedureBenign formLymphoplasmacytic inflammatory infiltratePrimary sclerosing cholangitisBiliary tract diseaseAbdominal painObliterative phlebitisAutoimmune processSclerosing cholangitisWhipple procedureInflammatory infiltrateInterstitial fibrosisClinical entityCase reportTract diseasePancreatic adenocarcinomaDifferential diagnosisPancreatic carcinomaPancreaticobiliary diseasesPathological overlap
2003
How to treat OCD in patients with Tourette syndrome
Miguel E, Shavitt RG, Ferrão YA, Brotto SA, Diniz JB. How to treat OCD in patients with Tourette syndrome. Journal Of Psychosomatic Research 2003, 55: 49-57. PMID: 12842231, DOI: 10.1016/s0022-3999(02)00583-4.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsObsessive-compulsive disorderTourette syndromeCognitive behavior therapyOCD patientsCircuit-based therapiesGonadal hormone systemsWorse treatment responsePresence of ticsRefractory patientsAutoimmune processReuptake inhibitorsSuch patientsCombined therapyResistant casesTreatment responseDrug treatmentPharmacological approachesNew therapiesPatientsEffective psychological interventionsTherapyHormone systemPsychological interventions
2001
Lupus autoantigens: Their origins, forms, and presentation
Doyle H, Yan J, Liang B, Mamula M. Lupus autoantigens: Their origins, forms, and presentation. Immunologic Research 2001, 24: 131-147. PMID: 11594452, DOI: 10.1385/ir:24:2:131.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusMaintenance of autoimmunityT cell compartmentCentral lymphoid organsT cell developmentAutoimmune processLupus erythematosusAntigenic sinAutoreactive cellsAutoimmune diseasesLymphoid organsPresenting cellsB lymphocytesImmune systemAutoimmunityCell compartmentNumber of mechanismsCell developmentInductionErythematosusCellsLupusForeign proteinsLymphocytesCostimulation
1996
Antigen-specific therapies for the treatment of autoimmune diseases
Hafler D, Weiner H. Antigen-specific therapies for the treatment of autoimmune diseases. 1996, 61-76. DOI: 10.1007/978-3-642-61191-9_6.Peer-Reviewed Original ResearchAntigen-specific therapyInfectious agentsMajor histocompatibility complexAutoimmune disordersAutoimmune diseasesT cellsLocal antigen-presenting cellsOrgan-specific autoimmune diseasesHuman autoimmune disordersAntigen-presenting cellsOrgan-specific proteinsRange of antigensAutoimmune processAutoimmune cascadeHistocompatibility complexDisordersTherapyDiseasePrimary targetCellsVirusOrgansAgentsSuperantigensEtiology
1994
Development of a Mouse Model for Nonbacterial Prostatitis
Keetch D, Humphrey P, Ratliff T. Development of a Mouse Model for Nonbacterial Prostatitis. Journal Of Urology 1994, 152: 247-250. PMID: 8201676, DOI: 10.1016/s0022-5347(17)32871-9.Peer-Reviewed Original ResearchConceptsNonbacterial prostatitisProstatic inflammationC57BL/6-lpr miceLpr miceBALB/c miceAdoptive transfer studiesCommon clinical entityDegree of inflammationBALB/cPeriglandular regionsAutoimmune processAJ miceLymphocytic infiltrationC57BL/6 miceClinical entityProstate antigenC miceImmune parametersSyngeneic miceProstatitisMouse modelProstatic tissueDisease processAnimal modelsInflammation
1993
Suppression of Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens
Weiner H, Miller A, Khoury S, Zhang Z, Al-Sabbagh A, Brod S, Lider O, Higgins P, Sobel R, Matsui M, Sayegh M, Carpenter C, Eisenbarth G, Nussenblatt R, Hafler D. Suppression of Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. 1993, 627-634. DOI: 10.1007/978-3-642-51479-1_81.Peer-Reviewed Original ResearchSuppressor T cellsAutoimmune diseasesOral administrationPeyer's patchesT cellsEpithelial cellsImmune systemAntigen-specific suppressor T cellsOrgan-specific autoimmune diseasesHuman gut epithelial cellsAutoreactive immune processesSpecific suppressor cellsPeripheral immune toleranceAntigen-presenting cellsClass II antigensAnti-idiotypic antibodiesAntigen-induced toleranceIntestinal epithelial cellsGut epithelial cellsHen's egg proteinsAutoimmune processOral toleranceSuppressor cellsImmune toleranceImmunologic tolerance
1989
Decrease of suppressor inducer (cd4+ 2h4+) t cells in multiple sclerosis cerebrospinal fluid
Chofflon M, Weiner H, Morimoto C, Hafler D. Decrease of suppressor inducer (cd4+ 2h4+) t cells in multiple sclerosis cerebrospinal fluid. Annals Of Neurology 1989, 25: 494-499. PMID: 2528316, DOI: 10.1002/ana.410250512.Peer-Reviewed Original ResearchConceptsInducer T cellsSuppressor-inducer T cellsMultiple sclerosis patientsT cellsCerebrospinal fluidMultiple sclerosisPeripheral bloodSclerosis patientsInducer cellsInducer functionMultiple sclerosis cerebrospinal fluidHelper-inducer T cellsCentral nervous system compartmentHelper inducer functionHelper-inducer cellsLocal autoimmune processesSuppressor-inducer functionSuppressor-inducer cellsCentral nervous systemSamples of bloodFlow cytometric analysisHelper inducerAutoimmune processInflammatory disordersT lymphocytes
1986
Pars Planitis and Autoimmune Endotheliopathy
Khodadoust A, Karnama Y, Stoessel K, Puklin J. Pars Planitis and Autoimmune Endotheliopathy. American Journal Of Ophthalmology 1986, 102: 633-639. PMID: 3777084, DOI: 10.1016/0002-9394(86)90537-4.Peer-Reviewed Original ResearchConceptsAutoimmune endotheliopathyPars planitisEndothelial rejection lineSpecific immune reactionsCorneal allotransplantationAutoimmune processCorneal changesClinical criteriaImmune reactionsPlanitisRejection lineVitreous humorIntact corneaEndotheliopathyAutoimmunePatientsAllotransplantationDiagnosisCornea
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply